Published by mark itwired
Posted on September 13, 2021
The rising prevalence of acute respiratory failures (ARF) due to the COVID-19 outbreak, risk of community infection, increasing demand for high flow nasal cannula, and advancements in high flow oxygen therapy devices are some key factors contributing to the growth of the high flow oxygen therapy devices market.
According to a recent study by Future Market Insights (FMI), these factors have proven crucial at enabling growth in the high flow oxygen therapy devices market. Sales of high flow oxygen therapy devices are expected to top US$ 1.7 Bn in 2021, at a CAGR of -6.4% during 2021-2025 and CAGR of 1.4% during the forecast period (2025-2031).
Public health issues worldwide, including Acute Respiratory Failure (ARF), pneumonia, asthma, and interstitial lung disease, pose a significant socioeconomic burden on individuals and societies.
Presently, COVID-19 is the primary risk factor for ARF. COVID-19 symptoms such as low blood-oxygen level and pneumonia in patients increase the risk of ARFs. Because of the growing ageing population and increased exposure to risk factors, ARF and pneumonia are becoming more prominent problems across the world, which is fuelling the demand for high flow oxygen therapy devices.
The World Health Organization (WHO) Child Health Epidemiology Reference Group estimates that the pneumonia resulted 105.7 million new cases in 2017; of these 13% were severe and needed immediate hospitalization.
Consistent rise in incidence of pneumonia will fuel the demand for high floe oxygen therapy devices through the forecast period. Indoor air pollution was a major risk factor that was estimated to have led to 29% of pneumonia deaths in 2017.
Outdoor air pollution was responsible for another 18% of all deaths. In addition, an increase of 81.1% in the number of pneumoconiosis cases were observed for both sexes from 1990 to 2017 worldwide. Thus, the growing burden of respiratory diseases along with the outbreak of COVID-19 across the world is expected to drive the high flow oxygen therapy devices market.
Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13794
“Increasing funding for R&D activities aimed launching novel products and solutions and healthcare recognition and recommendation of high-flow nasal cannula oxygen therapy will continue creating growth opportunities for manufacturers through the assessment period, ending in 2031,” says the FMI analyst
Some of the leading manufacturers of high flow oxygen therapy devices are focusing on product approvals and launch strategies for global expansion objectives, thereby, enhancing their market presence. The leading key players are also focusing on innovation and launching new technologies for increasing the efficiency of products.
The key market players covered by FMI include Draegerwerk AG & Co. KGaA, Teleflex Medical GmBH, Philips Respironics, Vapotherm, Inc., ResMed, Vyaire Medical, Inc., Fisher & Paykel Corporation Ltd., Armstrong Medical, Flexicare Medical, Hamilton Medical Inc., Intersurgical Inc., Inspired Medical, WILAMed GmBH, Besmed Health Business Corp, Shenzhen Micomme Medical Technology Development Co., Ltd, Shenyang RMS Medical Tech Co. Ltd. and BMC Medical Co., Ltd.
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global high flow oxygen therapy devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on high flow oxygen therapy devices segment based on the product (High Flow Nasal Cannulas, High Flow Oxygen Masks, Breathing Circuits, Heated Humidifiers and Accessories) Application (Pneumonia and Acute Respiratory Failure) End User (Less than 100 Beds Hospitals, 100-250 Beds Hospitals, 250-500 Beds Hospitals and 500 Beds and Above Hospitals) across seven major regions.
Any Queries, Contact us @ https://www.futuremarketinsights.com/ask-question/rep-gb-13794
The high flow oxygen therapy devices market will reach worth of US$ 1.7 Bn in the year 2021 and is expected to reach US$ 1.4 Bn by 2031 owing to the rising prevalence of acute respiratory failures due to the covid-19 pandemic.
High flow oxygen therapy devices are projected to record high demand in the forecast period. The overall market is forecast to exhibit a CAGR of -6.4% during 2021-2025 and 1.4% from 2025-2031.
Historically, the market has grown at a CAGR of 23.9% from 2016 to 2020.
Growing community infection to increase high flow nasal cannula and continuous product development and new launches are some of the prominent trends which drive the demand for high flow oxygen therapy devices.
The growing burden of respiratory diseases and increase in the ageing population are the major driving factors.
The cumulative market share of the top players including Koninklijke Philips N.V., Fisher & Paykel Corporation Ltd., Resmed Corporation, Drägerwerk AG & Co. KGaA and Teleflex Corporation constitutes around 64.8% of the overall fragmented market.
India, China, the U.S., India, Japan, China and Germany are the top 5 countries that are driving the demand for High Flow Oxygen Therapy Devices.
The post High Flow Oxygen Therapy Devices Market is expected to reach US$ 1.4 Billion by 2031 Across The Globe first appeared on Market Research Blog.
The rising prevalence of acute respiratory failures (ARF) due to the COVID-19 outbreak, risk of community infection, increasing demand for high flow nasal cannula, and advancements in high flow oxygen therapy devices are some key factors contributing to the growth of the high flow oxygen therapy devices market.
According to a recent study by Future Market Insights (FMI), these factors have proven crucial at enabling growth in the high flow oxygen therapy devices market. Sales of high flow oxygen therapy devices are expected to top US$ 1.7 Bn in 2021, at a CAGR of -6.4% during 2021-2025 and CAGR of 1.4% during the forecast period (2025-2031).
Public health issues worldwide, including Acute Respiratory Failure (ARF), pneumonia, asthma, and interstitial lung disease, pose a significant socioeconomic burden on individuals and societies.
Presently, COVID-19 is the primary risk factor for ARF. COVID-19 symptoms such as low blood-oxygen level and pneumonia in patients increase the risk of ARFs. Because of the growing ageing population and increased exposure to risk factors, ARF and pneumonia are becoming more prominent problems across the world, which is fuelling the demand for high flow oxygen therapy devices.
The World Health Organization (WHO) Child Health Epidemiology Reference Group estimates that the pneumonia resulted 105.7 million new cases in 2017; of these 13% were severe and needed immediate hospitalization.
Consistent rise in incidence of pneumonia will fuel the demand for high floe oxygen therapy devices through the forecast period. Indoor air pollution was a major risk factor that was estimated to have led to 29% of pneumonia deaths in 2017.
Outdoor air pollution was responsible for another 18% of all deaths. In addition, an increase of 81.1% in the number of pneumoconiosis cases were observed for both sexes from 1990 to 2017 worldwide. Thus, the growing burden of respiratory diseases along with the outbreak of COVID-19 across the world is expected to drive the high flow oxygen therapy devices market.
Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13794
“Increasing funding for R&D activities aimed launching novel products and solutions and healthcare recognition and recommendation of high-flow nasal cannula oxygen therapy will continue creating growth opportunities for manufacturers through the assessment period, ending in 2031,” says the FMI analyst
Some of the leading manufacturers of high flow oxygen therapy devices are focusing on product approvals and launch strategies for global expansion objectives, thereby, enhancing their market presence. The leading key players are also focusing on innovation and launching new technologies for increasing the efficiency of products.
The key market players covered by FMI include Draegerwerk AG & Co. KGaA, Teleflex Medical GmBH, Philips Respironics, Vapotherm, Inc., ResMed, Vyaire Medical, Inc., Fisher & Paykel Corporation Ltd., Armstrong Medical, Flexicare Medical, Hamilton Medical Inc., Intersurgical Inc., Inspired Medical, WILAMed GmBH, Besmed Health Business Corp, Shenzhen Micomme Medical Technology Development Co., Ltd, Shenyang RMS Medical Tech Co. Ltd. and BMC Medical Co., Ltd.
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global high flow oxygen therapy devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on high flow oxygen therapy devices segment based on the product (High Flow Nasal Cannulas, High Flow Oxygen Masks, Breathing Circuits, Heated Humidifiers and Accessories) Application (Pneumonia and Acute Respiratory Failure) End User (Less than 100 Beds Hospitals, 100-250 Beds Hospitals, 250-500 Beds Hospitals and 500 Beds and Above Hospitals) across seven major regions.
Any Queries, Contact us @ https://www.futuremarketinsights.com/ask-question/rep-gb-13794
The high flow oxygen therapy devices market will reach worth of US$ 1.7 Bn in the year 2021 and is expected to reach US$ 1.4 Bn by 2031 owing to the rising prevalence of acute respiratory failures due to the covid-19 pandemic.
High flow oxygen therapy devices are projected to record high demand in the forecast period. The overall market is forecast to exhibit a CAGR of -6.4% during 2021-2025 and 1.4% from 2025-2031.
Historically, the market has grown at a CAGR of 23.9% from 2016 to 2020.
Growing community infection to increase high flow nasal cannula and continuous product development and new launches are some of the prominent trends which drive the demand for high flow oxygen therapy devices.
The growing burden of respiratory diseases and increase in the ageing population are the major driving factors.
The cumulative market share of the top players including Koninklijke Philips N.V., Fisher & Paykel Corporation Ltd., Resmed Corporation, Drägerwerk AG & Co. KGaA and Teleflex Corporation constitutes around 64.8% of the overall fragmented market.
India, China, the U.S., India, Japan, China and Germany are the top 5 countries that are driving the demand for High Flow Oxygen Therapy Devices.
The post High Flow Oxygen Therapy Devices Market is expected to reach US$ 1.4 Billion by 2031 Across The Globe first appeared on Market Research Blog.
Explore more articles in the Research Reports category
